Streetbeat News

Price Targets

ALIT

Alight (NYSE:ALIT) received 4 analyst ratings in the last quarter, with 3 bullish, 1 somewhat bullish, and none bearish. The average 12-month price target among these analysts is $11.75, with a high of $13.00 and a low of $10.00. This target is a 9.62% decrease from the previous target of $13.00. Analyst ratings are based on financial analysis and provide guidance to investors, though they reflect opinions and can vary.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 12:00 pm

ACLX

Arcellx (NASDAQ:ACLX) has received 4 bullish analyst ratings in the last quarter, with no neutral or bearish ratings. The average 12-month price target for ACLX is $59.25, with a high of $65.00 and a low of $52.00. This target has increased by 10.4% from the previous average of $53.67. Analysts typically review stocks quarterly or after major company updates, basing their ratings on financial predictions and company risk assessments.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 12:00 pm

ADC

Mizuho analyst Haendel St. Juste has downgraded Agree Realty (NYSE:ADC) from Buy to Neutral and reduced the price target from $67 to $61.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:58 am

EOG

Morgan Stanley analyst Devin McDermott downgraded EOG Resources (NYSE:EOG) from Overweight to Equal-Weight and set a price target of $134.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:56 am

MRO

Morgan Stanley analyst Devin McDermott has downgraded Marathon Oil (NYSE:MRO) from Overweight to Equal-Weight and reduced the price target from $27 to $25.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:54 am

ETON

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Eton Pharmaceuticals (NASDAQ:ETON) and maintained a $10 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:43 am

ENTX

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Entera Bio (NASDAQ:ENTX) and maintained a price target of $10. This endorsement from the analyst could influence investor sentiment and potentially impact the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:42 am

ALIT

Needham analyst Kyle Peterson has reiterated a Buy rating on Alight (NYSE:ALIT) and maintained a $13 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:30 am

CRSP

JMP Securities analyst Silvan Tuerkcan has maintained a Market Outperform rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $74 to $80.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:29 am

BPMC

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and maintained the price target of $85. This reaffirmation of the company's stock rating and price target suggests continued confidence in Blueprint Medicines' prospects.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 11:28 am